What Happened?
South San Francisco, CA-based CytomX Appointed Sean McCarthy as Chief Executive Officer
About the Company
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company`s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, MD Anderson Cancer Center and ImmunoGen, Inc.
About the Person
Dr. McCarthy joined CytomX in 2011 and has more than twenty years of experience in the biotechnology industry encompassing roles in R&D management, business development and financing. Following completion of his post-doctoral training at the DNAX Research Institute (now Merck Palo Alto) Dr. McCarthy held research leadership and program management roles at Millennium Pharmaceuticals where he managed therapeutic protein discovery programs. From Millennium he joined SGX Pharmaceuticals where he spearheaded a wide range of pharma partnerships as Vice President Business Development. He also served on the SGX management team that led a successful initial public offering in 2006 (SGXP; subsequently acquired by Lilly). Prior to joining CytomX Dr. McCarthy was a transactional partner at Pappas Ventures responsible for investments in therapeutic, medical device and molecular diagnostic companies including LEAD Therapeutics (acquired by Biomarin), TyRx (acquired by Medtronic), Lumena (acquired by Shire). Dr. McCarthy is an author on multiple peer-reviewed scientific publications, issued patents and filed patent applications. He received his B.Sc. in biochemistry and pharmacology at King`s College, University of London; his M.B.A. from the Rady School of Management at UC San Diego; and a D. Phil. in cancer biology from St. John`s College, University of Oxford. Dr. McCarthy is a Board member of the California Life Sciences Association.
Info Source
Press Release
Short Profile